Claims for Patent: 8,940,718

Summary for Patent: 8,940,718

Title:	Antiviral compounds
Abstract:	The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
Assignee:	Gilead Sciences Inc
Application Number:	US13/679,874
Patent Claims:	1. A compound of formula (I): E1a-V1a—C(═O)—P1a—W1a—P1b—C(═O)—V1b-E1b (I) wherein W1a is and W1a is optionally substituted with one or more groups independently selected from halo, alkyl, haloalkyl, or cyano; Y5 is —O—CH2—, or —CH2—O—; X5 is —CH═CH—; E1a is —N(H)(alkoxycarbonyl), —N(H)(cycloalkylcarbonyl) or —N(H)(cycloalkyloxycarbonyl); or E1a-V1a taken together are R9a; E1b is —N(H)(alkoxycarbonyl), —N(H)(cycloalkylcarbonyl) or —N(H)(cycloalkyloxycarbonyl); or E1b-V1b taken together are R9b; V1a and V1b are each independently selected from: P1a is selected from: P1b is selected from: and R9a and R9b are each independently: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 which has formula: wherein the imidazole ring shown in formula A1 or A2 is optionally substituted with one or more groups independently selected from halo, haloalkyl, cyano, and alkyl; or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 which has formula: wherein the imidazole ring shown in formula A2 is optionally substituted with one or more groups independently selected from halo, haloalkyl, cyano, or alkyl; or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 wherein at least one of E1a and E1b is —N(H)(alkoxycarbonyl). 5. The compound of claim 1 wherein both of E1a and E1b is —N(H)C(═O)OMe. 6. The compound of claim 1 wherein both of E1a and E1b are —N(H)C(═O)OMe. 7. The compound of claim 1 wherein at least one of E1a and E1b is —N(H)(cycloalkylcarbonyl) or —N(H)(cycloalkyloxycarbonyl). 8. The compound of claim 1 wherein at least one of E1a and E1b is cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or cyclobutyloxycarbonylamino. 9. The compound of claim 1 wherein E1a and E1b are each independently selected from cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or methoxycarbonylamino. 10. The compound of claim 1 wherein at least one of V1a and V1b is: 11. The compound of claim 1 wherein E1a-V1a taken together are R9a or wherein E1b-V1b taken together are R9b. 12. The compound of claim 1 wherein at least one of P1a and P1b is selected from: 13. The compound of claim 1 wherein P1a and P1b are each independently selected from: 14. The compound of claim 1 wherein one of P1a and P1b is: and the other of P1a and P1b is: 15. The compound of claim 1 wherein one of P1a and P1b is: and the other of P1a and P1b is: 16. The compound of claim 1 wherein at least one of P1a and P1b is: 17. The compound of claim 1 wherein at least one of P1a and P1b is: 18. The compound of claim 1 wherein at least one of —V1a—C(═O)—P1a— and —P1b—C(═O)—V1b— is: 19. The compound of claim 1 wherein at least one of —V1a—C(═O)—P1a— and —P1b—C(═O)—V1b— is: 20. The compound of claim 1 wherein both of —V1a—C(═O)—P1a— and —P1b—C(═O)—V1b— are independently selected from: 21. The compound of claim 1 wherein one of —V1a—C(═O)—P1a— and —P1b—C(═O)—V1b— is: and the other of —V1a—C(═O)—P1a— and —P1b—C(═O)—V1b— is: 22. The compound of claim 1 which is a compound of formula: or a pharmaceutically acceptable salt thereof. 23. The compound of claim 1 which is a compound of formula: or a pharmaceutically acceptable salt thereof. 24. A pharmaceutical composition comprising the compound as described in claim 1 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier. 25. The pharmaceutical composition according to claim 24, further comprising an inhibitor of HCV NS5B polymerase. 26. A method of treating hepatitis C, said method comprising administering to a human patient a pharmaceutical composition which comprises a therapeutically effective amount of the compound as described in claim 1 or a pharmaceutically acceptable salt thereof. 27. The method according to claim 26, further comprising administering an interferon or a pegylated interferon to the patient. 28. The method according to claim 26, further comprising administering ribavirin to the patient.